Pfizer Starts Phase 1 Study of PF-08653944 in Adults With Overweight or Obesity
Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.